The seasonal window for respiratory syncytial virus protection opens next month, which turns an abstract choice into a scheduling decision for any household expecting a baby this fall.
There are two routes to protection, and for most infants, only one is needed. A pregnant patient can receive the maternal RSV vaccine, Pfizer's Abrysvo, between 32 and 36 weeks of gestation. Or the baby can receive a long-acting monoclonal antibody after birth. Either path is intended to cover the same stretch of life, the first months, when an infant's airways are smallest, and the hospitalization risk is highest.
RSV is the leading cause of infant hospitalization in the United States. About two to three of every 100 babies younger than three months are hospitalized for it each year, and severe cases sometimes require oxygen support or mechanical ventilation. Nearly every child is infected at least once by age two, but the first winter is when a common virus becomes a hospital admission.
The Numbers Behind Each Route
Surveillance data now cover a full season with both products in wide use. A CDC-led analysis published in the agency's weekly report found that among infants aged 0 to 7 months, RSV-associated hospitalization rates during the 2024 to 2025 season were 43 percent lower in one national surveillance network and 28 percent lower in a second, compared with pooled prepandemic rates, according to the MMWR report. The largest reductions in both networks were among babies aged 0 to 2 months.
For the maternal route specifically, a University of Pittsburgh and UPMC study published in JAMA Network Open in June estimated 68 percent effectiveness against RSV-associated hospitalization and 69 percent against more severe lower respiratory tract disease among infants younger than three months. That analysis drew on health records from western Pennsylvania across the 2023 to 2024 and 2024 to 2025 seasons.
"We designed this study to focus on what matters most to families: whether their baby might end up in the hospital," said lead author Dr. Anne-Marie Rick, an assistant professor of pediatrics at Pitt and a physician at UPMC Children's Hospital of Pittsburgh, in a university statement. Two caveats belong alongside the number. The study was observational, so residual confounding cannot be ruled out, and it was funded by Pfizer through a collaboration with the university, with several authors reporting company support and Pfizer employees among the co-authors. The estimates were consistent with earlier clinical trial results and with independent national surveillance, which is why they are worth weighing rather than dismissing.
Timing Is the Part Most Households Get Wrong
The calendar matters more than the choice between products. The maternal vaccine is recommended during 32 through 36 weeks of pregnancy and is given seasonally, September through January, in most of the continental United States, according to CDC guidance. Patients further along than 36 weeks and six days are not vaccinated, because it is unlikely to be enough time for antibodies to develop and cross the placenta.
That transfer window is also why the two routes occasionally overlap. Infants born within 14 days of maternal vaccination are recommended to receive the infant antibody as well. Except in rare circumstances, babies born 14 or more days after their mother was vaccinated do not need it.
Infant antibodies follow a different clock. One dose of nirsevimab, sold as Beyfortus, or clesrovimab, sold as Enflonsia, is recommended for infants under eight months born during or entering their first RSV season, with administration running October through March in most of the country, per CDC infant guidance. Babies born during that window should receive it within about a week of birth, ideally during the birth hospitalization. Nirsevimab is also recommended for some children aged 8 to 19 months at increased risk of entering a second season; clesrovimab is not approved for that use.
CDC does not name a preferred product and advises providers to discuss both the maternal vaccine and the infant antibody with parents, considering family preferences. The American College of Obstetricians and Gynecologists takes a similar approach in its practice advisory. Supply and delivery timing are legitimate parts of the conversation.
Questions Worth Bringing to the Next Appointment
A short list makes the visit more useful. Ask where the estimated delivery date falls relative to the 32 to 36 week window, because a baby due in October implies a different plan than one due in February. Ask whether the practice stocks the maternal vaccine and administers it in the office, or whether a referral to a pharmacy is required. Ask whether the birth hospital administers the infant antibody before discharge and whether it stocks nirsevimab, clesrovimab, or both.
One rule surprises many families. CDC does not currently recommend repeat maternal vaccination in later pregnancies once a patient has received a dose. Infants of subsequent pregnancies should receive the antibody instead.
Cost is usually not the obstacle it appears to be. Most insurance plans cover recommended immunizations without cost sharing, and the federal Vaccines for Children program covers nirsevimab and clesrovimab for eligible uninsured and underinsured infants at participating providers. Families should still confirm coverage before delivery rather than after.
MedicalDaily previously reported on how vaccines given during pregnancy cover a newborn's first months before any infant shots begin.
The Symptoms That Change the Plan
Protection reduces severe illness. It does not prevent every infection, and parents should still know what escalation looks like. In young infants, RSV may not begin with an obvious cough. Irritability, reduced activity, and poor feeding can be the first signs, as the CDC notes for infants.
Fast or labored breathing, chest retractions where the skin pulls in between the ribs, flaring nostrils, wheezing, a bluish tint around the lips, dehydration with fewer wet diapers, or pauses in breathing all require urgent evaluation. Any of those in a baby under three months warrants immediate care rather than a wait-and-see approach.
What remains unsettled is durability. The Pittsburgh researchers are extending their analysis through additional seasons and to infants up to 180 days old, which should clarify how long maternal protection holds. Federal guidance for this season is unchanged, and CDC administration windows govern when providers may begin giving each product.
Key Questions Answered
Does a baby need both the maternal vaccine and the infant antibody? In most cases, no. One route is recommended. The exception is a baby born within 14 days of the parent's vaccination, or specific clinical situations where transferred protection may be inadequate.
When should the maternal vaccine be given? Between 32 and 36 weeks of pregnancy, during the September through January window in most of the continental United States.
When does the infant's antibody get administered? Generally, October through March, and within about a week of birth for babies born during the season, ideally before hospital discharge.
Is one antibody product better than the other? CDC does not express a preference between nirsevimab and clesrovimab for infants. Availability at the birth hospital or pediatric office is the practical deciding factor.
How much protection do these provide? National surveillance found infant hospitalization rates 43 percent and 28 percent lower across two networks in the first full season with both products available, and a Pennsylvania study estimated about 68 percent effectiveness for maternal vaccination in babies under three months.
Who funded the Pennsylvania study? Pfizer, which makes the maternal vaccine, funded it through a collaboration with the University of Pittsburgh, and several authors reported company support.
What does severe RSV look like in a newborn? Fast or labored breathing, chest retractions, poor feeding, fewer wet diapers, bluish lips, or pauses in breathing. Any of these in a young infant needs urgent evaluation.
